TP53 and cancer: Clinical trials using a p53-expressing replication-deficient adenovirus vector (Ad-p53) have been performed in patients with various types of cancers, and its feasibility has been confirmed.12, 13, 14 Moreover, p53-expressing conditionally replicating adenovirus vectors represent promising agents in the cancer treatment.